Meeting NewsVideo

VIDEO: Factor XI inhibitors offer potentially safer anticoagulant therapy

ORLANDO — In this video at the ASH Annual Meeting and Exposition, Jeffrey I. Weitz, MD, FRCPC, professor of medicine and executive director of the Thrombosis and Atherosclerosis Research Institute at McMaster University in Hamilton, Canada, discusses his lecture on the role of factor XI inhibitors in anticoagulant therapy.

“The ultimate goal of anticoagulant therapy is to attenuate thrombosis without affecting hemostasis,” he told Healio. “We haven’t achieved that goal, although the direct oral anticoagulants are a huge advance over vitamin K antagonists, with about a 50% reduction in the risk of intracranial hemorrhage. Still, bleeding is the major side effect, and factor XI inhibitors have the potential to be safer anticoagulants, and thereby to be associated with a lower risk of bleeding.”

Disclosure: Weitz reports receiving consulting and/or honoraria fees from Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer and Portola.

ORLANDO — In this video at the ASH Annual Meeting and Exposition, Jeffrey I. Weitz, MD, FRCPC, professor of medicine and executive director of the Thrombosis and Atherosclerosis Research Institute at McMaster University in Hamilton, Canada, discusses his lecture on the role of factor XI inhibitors in anticoagulant therapy.

“The ultimate goal of anticoagulant therapy is to attenuate thrombosis without affecting hemostasis,” he told Healio. “We haven’t achieved that goal, although the direct oral anticoagulants are a huge advance over vitamin K antagonists, with about a 50% reduction in the risk of intracranial hemorrhage. Still, bleeding is the major side effect, and factor XI inhibitors have the potential to be safer anticoagulants, and thereby to be associated with a lower risk of bleeding.”

Disclosure: Weitz reports receiving consulting and/or honoraria fees from Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer and Portola.

    See more from Discoveries from ASH: Benign Hematology